Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-94676 in metastatic castration-resistant prostate cancer
NCT04428788Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2020
- Primary completion
- Oct 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-986365 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Celgene Corporation. Primary endpoints: Adverse Events, Dose-Limiting Toxicity at 35 days and 2 more. Started Jun 2020; status: completed.
02
Drugs
BMS-986365
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04428788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04428788.